Bayers, Billion

Bayer's $7.25 Billion Roundup Ceiling Is Enforceable — The Payment Schedule Is Another Matter

Published on 11/22/2026 at 07:21 | Editorial boerse-global.de
Berenberg lifted Bayer's price target to EUR 62 from EUR 53.50, keeping Hold, as a Missouri court approved Monsanto's Roundup settlement of up to USD 7.25 billion.
Bayers, Billion, Roundup, Ceiling, Enforceable, The, Payment, Schedule, Another, Matter Illustration mit AI erstellt.

Berenberg lifted its price target on Bayer shares from EUR 53.50 to EUR 62.00 on 18 November, keeping a "Hold" rating on the stock. The revision landed in the same week that a Missouri court gave final approval to Monsanto's nationwide Roundup settlement — a decision that settles the size of Bayer's glyphosate liability far more firmly than it settles the timing of the cash leaving the company.

The stock rose 1.2% on Friday to EUR 55.16, still trading below the broker's new target.

A cap, not a cheque

Judge Timothy Boyer approved the settlement in Missouri, but the ruling is not yet final and binding. The agreement with tens of thousands of plaintiffs provides for payments of up to USD 7.25 billion spread over as many as 21 years, with the ceiling already accounting for sums Bayer has paid out to date. Annual instalments are capped and are designed to decline over time.

That structure matters for anyone modelling Bayer's cash flow. A single headline figure of USD 7.25 billion says little about what leaves the balance sheet in any given year — and an appeal could suspend the payments altogether until the appeals process runs its course. Whether one is filed has not been disclosed.

Chief executive Bill Anderson called the approval a decisive milestone in containing pending and potential future litigation. Bayer has consistently denied that Roundup causes cancer, and the settlement carries no admission of liability.

Should investors sell immediately? Or is it worth buying Bayer?

Who the fund covers — and who it doesn't

The agreement is intended to capture the bulk of current and possible future US claims tied to non-Hodgkin lymphoma. It also covers compensation for people diagnosed within 16 years of the settlement taking effect, provided they were exposed to Roundup before 17 February.

How many claimants have signed on has not been published, leaving the reach of the deal dependent on how many affected parties choose to resolve their claims through the fund. Reuters puts the number of pending claims at roughly 65,000. About 200 cases before federal courts fall outside the settlement entirely.

The longer ledger

Since acquiring Monsanto in 2018, Bayer has already paid out around USD 10 billion in settlements, according to Deutschlandfunk. A June ruling by the US Supreme Court added another layer of protection, excluding certain claims that Roundup packaging lacked cancer warnings.

Against that history, the Missouri approval gives the compensation framework a long-term payment horizon rather than an immediate bill. For financial planning, the next question is narrower and more concrete: whether an appeal materialises, and how far it pushes back the first instalments.

The pipeline's own headline

Bayer had a second piece of news to digest this week. The FDA has approved asundexian under the brand name Sunharbo to reduce the risk of further strokes in adults who have suffered a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack. According to Bayer, it is the first approved factor XIa inhibitor.

Two regulatory and legal wins in quick succession gave analysts something to work with. Berenberg's move suggests the broker sees more value in the equity than the market has yet priced in — though its Hold rating implies the shares, at EUR 55.16, still have ground to cover before the target is in reach.

Ad

Bayer Stock: New Analysis - 22 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70543910 |